CORDIS
EU research results

CORDIS

English EN

European Consortium on Synaptic Protein Networks in Neurological and Psychiatric Diseases

Project information

Grant agreement ID: 241498

Status

Closed project

  • Start date

    1 January 2010

  • End date

    30 June 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 806 674,27

  • EU contribution

    € 11 952 691

Coordinated by:

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

Objective

Signalling at nerve cell synapses - a key determinant of all aspects of brain function - depends on the function of hundreds of synaptic proteins and their interactions. Numerous recent studies showed that a wide range of neurological and psychiatric diseases are 'synaptopathies' whose onset and progression are due to mutations of synaptic proteins and subsequent synaptic dysfunctions. EUROSPIN will pursue a multilevel systems biology approach to determine mechanistic relationships between mutations of synaptic proteins and neurological and psychiatric diseases, and to develop new diagnostic tools and therapies. Our concept is based on the current knowledge of disease genes, which we will continuously extend with new human genetic data and complement with large-scale screens of mutant mice in order to identify and characterize disease-relevant mutations in synaptic proteins and corresponding mouse models. Proteomic tools will be used to analyse the protein components of synapses, and protein interaction networks of synaptic disease gene products will be mapped systematically. In parallel, smart libraries will be employed to develop small molecules for perturbing the functions and interactions of disease gene products. Functional models of disease-relevant protein networks will be generated and used to formulate hypotheses as to how specific mutations might affect synaptic physiology and network function, and thus cause disease. These hypotheses will initially be tested in reduced systems by novel physiological and imaging methods. Well-validated disease gene products, the consequences of their dysfunction in disease, and therapeutic modifications of their dysfunction will then be studied in mouse models in vivo, applying novel electrophysiological, imaging, and behavioural techniques. The combined information obtained in the EUROSPIN program will be used for the development of new diagnostic tools and therapeutic interventions that can be tested in patients.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Address

Hofgartenstrasse 8
80539 Munich

Germany

Activity type

Other

EU Contribution

€ 2 845 290

Administrative Contact

Nils Brose (Prof.)

Participants (17)

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

Netherlands

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Israel

EU Contribution

€ 301 440

MEDICAL RESEARCH COUNCIL

United Kingdom

EU Contribution

€ 206 133,50

GENOME RESEARCH LIMITED

United Kingdom

EU Contribution

€ 452 922,52

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)

Germany

EU Contribution

€ 692 034

UNIVERSITA DEGLI STUDI DI MILANO

Italy

EU Contribution

€ 478 200

UCL Elizabeth Garrett Anderson Institute for Women’s Health

United Kingdom

EU Contribution

€ 580 307

UNIVERSITY OF HAIFA

Israel

EU Contribution

€ 554 748

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 1 948 514,48

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 575 200

Novartis Forschungsstiftung

Switzerland

Synaptic Systems

Germany

EU Contribution

€ 562 987

SYNAPTOLOGICS BV

Netherlands

EU Contribution

€ 988 425

Synome Ltd

United Kingdom

EU Contribution

€ 325 993

RIKEN THE INSTITUTE OF PHYSICAL ANDCHEMICAL RESEARCH

Japan

EU Contribution

€ 236 735,50

FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH FONDATION

Switzerland

EU Contribution

€ 616 439

STICHTING VU

Netherlands

EU Contribution

€ 587 322

Project information

Grant agreement ID: 241498

Status

Closed project

  • Start date

    1 January 2010

  • End date

    30 June 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 806 674,27

  • EU contribution

    € 11 952 691

Coordinated by:

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany